UQ1 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Regulatory Progress (AMT-130)FDA alignment to accept three-year AMT-130 data as the primary basis for an accelerated BLA and agreed confirmatory study design materially de-risks the path to approval. This durable regulatory foothold shortens timelines, clarifies requirements, and enhances the program's strategic value across markets.
Clinical Signal (AMT-260)Early, large-magnitude seizure reductions and favorable tolerability in AMT-260's low-dose cohort demonstrate biological activity in a high-unmet-need neurology indication. If durable and replicated in higher doses, this supports progression to pivotal studies and expands uniQure's long-term neurology franchise potential.
Strengthened Funding RunwayA sizable equity raise materially increases near-to-medium term liquidity to fund BLA submission, confirmatory trials, and R&D across multiple gene therapy programs. This reduces immediate refinancing risk and supports continued investment in high-cost, long‑lead clinical development activities.
Bears Say
Persistent Cash BurnSustained large negative operating and free cash flows indicate reliance on external financing to fund operations and trials. Over a multi‑quarter horizon this elevates dilution and execution risk, constraining strategic flexibility and making program progression contingent on continued capital access.
Modest Revenue BaseA small recurring revenue base relative to R&D and SG&A spend means the company is not self‑funding. Continued losses and weak margins require sustained external funding or successful partner commercialization to reach profitability, limiting resilience to development setbacks.
Balance-sheet VolatilityHistorical swings into negative equity and volatile leverage reflect capital‑structure instability. Such volatility can raise financing costs, constrain covenant headroom, and complicate long-term planning, making sustained investment and partner negotiations more challenging during program commercialization stages.
uniQure News
UQ1 FAQ
What was uniQure N.V.’s price range in the past 12 months?
Currently, no data Available
What is uniQure N.V.’s market cap?
uniQure N.V.’s market cap is CHF2.38B.
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Aug 04, 2026 which is in 25 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on May 05, 2026. The company reported -$0.684 earnings per share for the quarter, beating the consensus estimate of -$0.696 by $0.012.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -0.66.
How many shares outstanding does uniQure N.V. have?
Currently, no data Available
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -$0.684 in its last earnings report, beating expectations of -$0.696. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of uniQure N.V.?
Currently, no hedge funds are holding shares in CH:UQ1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
uniQure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF53.67 (― Downside)
CHF53.67 (― Downside)
Insider Transactions
Sold Shares
Worth CHF778.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
201.17%
12-Months-Change
Fundamentals
Return on Equity
-145.81%
Trailing 12-Months
Asset Growth
28.63%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
UQ1 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated major positive clinical advances (notably strong 3‑year AMT‑130 efficacy, supportive Fabry and TLE data) and a strengthened balance sheet, but these were tempered by significant regulatory resistance from the FDA (recommendation for a sham‑controlled Phase III), safety‑related pauses/holds in two programs (AMT‑191 dosing pause and AMT‑162 hold), and a substantial year‑over‑year revenue decline. Management emphasized active regulatory engagement, continued data generation (4‑year AMT‑130 analysis) and pursuit of ex‑U.S. pathways and early access options, while acknowledging material uncertainty around Phase III design, cost and feasibility.View all CH:UQ1 earnings summariesUQ1 Stock 12 Month Forecast
Average Price Target
$53.67
Options Prices
Currently, No data available
---